These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12438536)

  • 1. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats.
    Zuideveld KP; Rusiç-Pavletiç J; Maas HJ; Peletier LA; Van der Graaf PH; Danhof M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1130-7. PubMed ID: 12438536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats.
    Fuller RW; Perry KW
    J Pharmacol Exp Ther; 1989 Jan; 248(1):50-6. PubMed ID: 2521515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
    Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
    Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An analysis of the hypothermic action of 8-hydroxy-2-(di-N-propylamino)tetralin, 1-(2-pyrimidinyl)piperazine and its derivatives].
    Komissarov IV; Dolzhenko AT; Obraztsova OG; Zin'kovskaia LIa
    Biull Eksp Biol Med; 1990 Mar; 109(3):275-7. PubMed ID: 2142007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
    Mokrosz JL; Dereń-Wesołek A; Tatarczyńska E; Duszyńska B; Bojarski AJ; Mokrosz MJ; Chojnacka-Wójcik E
    J Med Chem; 1996 Mar; 39(5):1125-9. PubMed ID: 8676348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
    Wong H; Dockens RC; Pajor L; Yeola S; Grace JE; Stark AD; Taub RA; Yocca FD; Zaczek RC; Li YW
    Drug Metab Dispos; 2007 Aug; 35(8):1387-92. PubMed ID: 17494642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone, ipsapirone and 1-(2-pyrimidinyl)-piperazine decrease cold-induced thyrotropin secretion in rats.
    Broqua P; Baudrie V; Bluet-Pajot MT; Chaouloff F
    Eur J Pharmacol; 1991 Nov; 204(2):141-7. PubMed ID: 1687218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine.
    Miller LG; Thompson ML; Byrnes JJ; Greenblatt DJ; Shemer A
    J Clin Psychopharmacol; 1992 Oct; 12(5):341-5. PubMed ID: 1362206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats.
    Zuideveld KP; Van der Graaf PH; Newgreen D; Thurlow R; Petty N; Jordan P; Peletier LA; Danhof M
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1012-20. PubMed ID: 14718609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonist in the learned helplessness paradigm in rats.
    Martin P
    Psychopharmacology (Berl); 1991; 104(2):275-8. PubMed ID: 1678895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The central action of 1-(2-pyrimidinyl)-piperazine, an ipsapirone metabolite.
    Tatarczyńska E; Pawłowski L; Chojnacka-Wójcik E; Maj J
    Pol J Pharmacol Pharm; 1989; 41(1):51-61. PubMed ID: 2587437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT-1A receptor responsiveness following subchronic administration of buspirone.
    Khan A; Haleem DJ
    Pak J Pharm Sci; 2006 Oct; 19(4):333-7. PubMed ID: 17105715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of buspirone in autistic children.
    Edwards DJ; Chugani DC; Chugani HT; Chehab J; Malian M; Aranda JV
    J Clin Pharmacol; 2006 May; 46(5):508-14. PubMed ID: 16638734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy.
    Haleem DJ; Shireen E; Haleem MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1323-9. PubMed ID: 15588759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of fluoxetine and WAY100635 improves short-term memory function.
    Fernández-Pérez S; Pache DM; Sewell RD
    Eur J Pharmacol; 2005 Oct; 522(1-3):78-83. PubMed ID: 16214127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by high-performance liquid chromatography with coulometric detection.
    Odontiadis J; Franklin M
    J Pharm Biomed Anal; 1996 Jan; 14(3):347-51. PubMed ID: 8851759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indorenate produces antidepressant-like actions in the rat forced swimming test via 5-HT1A receptors.
    Martínez-Mota L; Estrada-Camarena E; López-Rubalcava C
    Psychopharmacology (Berl); 2002 Dec; 165(1):60-6. PubMed ID: 12474119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats.
    Haleem DJ; Khan NH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):645-51. PubMed ID: 12787852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effect of buspirone and 1-(2-pyrimidinyl)-piperazine on cerebral glucose utilization in the rat.
    Grasby P; Sharp T; Moorman J; Grahame-Smith D
    Eur J Pharmacol; 1993 Jan; 230(1):41-6. PubMed ID: 8094054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.